Scienture Holdings Inc

Scienture Holdings Inc(MEDS)股票分析

$1.165

-0.053 (-4.51%)收盘时

Loading chart…
最高
1.240
开盘
1.200
成交量加权均价
1.18
成交量
114.44K
市值
18.51M
最低
1.130
成交额
134.84K
企业价值/息税折旧摊销前利润(TTM)
0.00

DataMeds AI, Inc., formerly Wellgistics Health, Inc., is a holding company. It is engaged in health information technology (IT) that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. The Company conducts its business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC, and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows clinical services to be connected to its health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, prescription price transparency, and provide additional concierge services.

AI 分析 of Scienture Holdings Inc (MEDS)

卖出

TRxADE Health Inc (MEDS) is not a good buy right now due to significant financial losses and poor technical indicators. The current price is $1.17, with a 5-day change of -39.32% and a year-to-date change of -66.90%. The RSI is at 9.228, indicating that the stock is extremely oversold, but this does not guarantee a rebound. The main risk is the company's negative net income, which reached -$18,363,225 in Q2 2026, reflecting ongoing financial instability.

估值指标

Scienture Holdings Inc(MEDS)当前预期市盈率为 0.00,5 年平均预期市盈率为 21.83。

预期市盈率

严重低估
5 年均值 P/E
21.83
当前P/E
0.00
高估
21.83
低估
21.83

预期 EV/EBITDA

严重高估
5 年均值 EV/EBITDA
-0.01
当前EV/EBITDA
0.00
高估
-0.01
低估
-0.01

预期市销率

严重低估
5 年均值 P/S
1.43
当前P/S
0.00
高估
1.43
低估
1.43

事件时间线

2026-11-05 (ET)

10:00:00

DataMeds AI Signs MOU with Florida HMO

2026-11-03 (ET)

18:30:00

DataMeds AI Terminates Letter of Intent with Datavault AI

2026-11-02 (ET)

06:30:00

DataMeds AI Subsidiary Corexa Health Signs Drug Supply Agreement

2026-10-22 (ET)

08:30:00

Datavault AI Plans to Acquire 19.9% Stake in DataMEDS

08:00:00

DataMEDS Enters into Letter of Intent with Datavault AI

资讯

MEDS 常见问题 —— 由 Alphio AI 解答

DataMeds AI, Inc., formerly Wellgistics Health, Inc., is a holding company. It is engaged in health information technology (IT) that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. The Company conducts its business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC, and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows clinical services to be connected to its health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, prescription price transparency, and provide additional concierge services. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

TRxADE Health Inc (MEDS) is not a good buy right now due to significant financial losses and poor technical indicators. The current price is $1.17, with a 5-day change of -39.32% and a year-to-date change of -66.90%. The RSI is at 9.228, indicating that the stock is extremely oversold, but this does not guarantee a rebound. The main risk is the company's negative net income, which reached -$18,363,225 in Q2 2026, reflecting ongoing financial instability.

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易